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Retinoblastoma is the most common intraocu-lar malignancy in childhood.1 In developed countries, most patients present with confined, 
intraocular disease. Secondary to late presentation, ad-
vanced retinoblastoma (locally advanced and metastatic 
disease) is more common in developing countries and 
is associated with exceedingly poor prognosis. In these 
cases, response to conventional therapies (enucleation, 
external-beam radiotherapy, and chemotherapy) has 
been poor. Several groups have proposed the use of 
high-dose chemotherapy in these patients; however, 
only a limited number of studies have addressed the role 
of high-dose chemotherapy followed by stem cell trans-
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BaCKgROunD anD OBjECtIVES: in recent years, there has been an increasing role for stem cell transplanta-
tion in the management of retinoblastoma. the aim of this study was to systematically review the role high-dose 
chemotherapy followed by stem cell transplantation in the treatment of patients with metastatic or relapsed, tri-
lateral or bilateral advanced retinoblastoma, and in patients with tumor at the surgical margin of the optic nerve 
and/or extrascleral extension.
DESIgn: systematic literature review. 
mEthODS: We performed an extensive Pubmed database search on 25 february 2012 for studies describing 
the use of high-dose chemotherapy followed by stem cell transplantation in the management of patients with 
retinoblastoma. 
RESuLtS: We located 15 studies that met the inclusion criteria and that included 101 patients. following treat-
ment for metastatic and relapsed disease, 44 of 77 patients (57.1%) were alive with no evidence of disease at the 
time of follow-up. however, a higher rate of local relapse developed in patients with Cns metastases (73.1%), 
which dropped to 47.1% in patients who received thiotepa. in patients with trilateral or bilateral advanced retino-
blastoma, 5 of 7 (71.4%) with reported outcome data were alive with no evidence of disease at the time of follow-
up. in patients with tumor at the surgical margin of the optic nerve and/or extrascleral extension, 6 of 7 patients 
(85.7%) were alive with no evidence of disease at the time of follow-up. 
COnCLuSIOnS: Durable tumor control is possible in patients with non-Cns metastases, trilateral or bilateral 
advanced retinoblastoma, and in patients with tumor at the surgical margin of the optic nerve and/or extrascleral 
extension. Patients with Cns metastases require thiotepa to improve tumor control. 
plantation in the treatment of patients with metastatic 
or relapsed, trilateral or bilateral advanced retinoblas-
toma, and for patients with tumor at the surgical mar-
gin of the optic nerve and/or extrascleral extension.2-16 
The aim of this study was to systematically review and 
investigate the current role of stem cell transplantation 
in the management of retinoblastoma.
mEthODS
A comprehensive PubMed search was conducted on 25 
February 2012. The following search terms were used; 
“retinoblastoma”, “chemotherapy”, “high-dose”, “stem 
cell” and “transplant”. No restrictions were applied to 
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the date of publication; however, this search was limited 
to papers in English. Reports describing the utilization 
of high-dose chemotherapy followed by stem cell trans-
plantation in the management of patients with retino-
blastoma were considered. Studies addressing the role 
of chemotherapy were excluded if no direct mention 
was made to the rescue of the bone marrow with subse-
quent stem cell transplantation. Furthermore, reference 
lists of included studies were hand-searched to identify 
relevant missing publications. Articles were assessed 
and selected for inclusion by all authors. Full text ar-
ticles of eligible abstracts were reviewed. Only original 
studies were included. Data pertaining to date of publi-
cation, study design and period, country of origin, num-
ber of patients, indication for treatment, chemotherapy 
regimen, therapeutic outcomes and associated toxicity 
were extracted using a predefined datasheet. Adequate 
high-dose chemotherapy regimens were defined as 
those consisting of a platinum agent and an alkylating 
compound in addition to etoposide.17 Due to its excel-
lent CNS penetration, the impact of thiotepa on the 
incidence of CNS relapse in patients with metastatic 
retinoblastoma was evaluated.18 
RESuLtS
The preliminary search yielded 53 abstracts. Three non-
English publications were excluded. Of the remaining 
50 studies, 20 were excluded following the first screen 
of the title and abstract. Thirty full-text articles were 
retrieved for detailed evaluation of which 17 were in-
eligible (did not address the use of high-dose chemo-
therapy followed by stem cell transplantation (n=16) 
or reported overlapping patient populations (n=1). 
Additionally, 2 papers were identified from the refer-
ence lists of included reports. Overall, 15 studies, which 
include 101 patients, met the inclusion criteria and 
formed the basis of this systematic review (Figure 1). 
The analysis involved 77 patients with metastatic or re-
lapsed retinoblastoma (13 articles; Table 1), 17 patients 
with trilateral or bilateral advanced retinoblastoma (3 
articles; Table 2), and 7 patients with tumor at the 
surgical margin of the optic nerve and/or extrascleral 
extension (2 articles; Table 3). Since most studies were 
retrospective in nature and reported on a heterogenous 
group of patients, strict inclusion and exclusion criteria 
could not be assessed. 
Secondary to the poor overall prognosis of reti-
noblastoma cases with CNS metastases, we opted to 
classify metastatic retinoblastoma patients into those 
presenting with or without CNS disease. Of a total of 
77 included patients, 26 and 43 patients presented with 
CNS and non-CNS metastases, respectively, while 
only 8 patients in this group harbored isolated orbital 
relapse.2-14 Of 69 patients who received high-dose che-
motherapy, 53 patients (76.8%) received an adequate 
chemotherapy combination. Treatment-associated 
morbidity data were available in 7 reports and con-
sisted mainly of grade IV hematological and gastroin-
testinal toxicity.3,4,7,8,11-13 One patient died secondary to 
this intensive chemotherapy protocol.6 Overall, 44 pa-
tients (57.1%) were alive with no evidence of disease 
at the time of follow-up. Treatment outcome was not 
as good in patients presenting with CNS metastases 
where 19 of 26 patients (73.1%) eventually developed 
CNS relapse, probably secondary to the use of inap-
propriate chemotherapeutic regimens (associated with 
poor CNS penetration); only 8 of 17 (47.1%) patients 
who received thiotepa subsequently developed CNS 
relapse.2-14 
Eight patients had trilateral retinoblastoma while 
9 harbored bilateral advanced disease.10,15,16 Lee et al16 
reported neutropenic fever and hepatic veno-occlusive 
disease in 9 of 9 and 2 of 9 patients, respectively. In ad-
dition, Dunkel and colleagues10 reported on 1 patient 
who died due to septicemia and multi-organ system 
failure secondary to chemotherapy. Overall, 5 of the 7 
patients (71.4%) with reported outcome data were alive 
with no evidence of disease at the time of follow-up.10,15
Seven patients with tumors at the surgical margin 
of the optic nerve and/or extrascleral extension were 
treated with high-dose chemotherapy followed by stem 
cell transplantation.2,4 Kremens et al4 reported grade IV 
gastrointestinal treatment-related toxicity; however, no 
treatment-related mortality was reported. Overall, 6 of 
7 patients (85.7%) were alive with no evidence of dis-
ease at the time of follow-up.2,4
DISCuSSIOn 
This study represents the first detailed systematic re-
view addressing the role of high-dose chemotherapy 
followed by stem cell transplantation in retinoblastoma. 
Unfortunately, most of the included studies were small 
retrospective case series (n=9)2-4,6,8,10,12,13,16 or single case 
reports (n=5).5,7,9,11,14 There was only one prospective 
report that addressed the use of stem cell transplant 
in pediatric malignancies in general and included 1 
patient with trilateral retinoblastoma.15 In addition, 
most of the reviewed reports originated from developed 
countries (n=12).2,4-8,11-16 According to our review, the 
use of high-dose chemotherapy followed by stem cell 
transplantation in retinoblastoma patients was first 
proposed by Matsubara et al8 in 1986. Since then, this 
treatment regimen has been expanded to include pa-
tients with tumors at the surgical margin of the optic 
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nerve and/or extrascleral extension (first patient treat-
ed in 1989)2 and trilateral retinoblastoma (first patient 
treated in 1997).10 
The treatment protocol in the majority of included 
studies consisted of induction poly-chemotherapy 
(with the aim of achieving partial or complete tumor 
response) followed by high-dose chemotherapy and au-
tologous stem cell transplantation. Only one case report 
narrated the performance of allogeneic stem cell trans-
plantation using an identical HLA-matched sibling.5 In 
conjunction with high-dose chemotherapy, external-
beam irradiation (for bulky, metastatic sites) has been 
reported 7 studies2,3,6,8,10,12,13 while intra-thecal chemo-
therapy and radio-immunotherapy were reported in 4 
studies.4,5,8,10 On the other hand, prophylactic cranial ir-
radiation was less commonly prescribed. However, due 
to the non-randomized nature of the included studies 
and the variability of treatment protocols among pa-
tients in each study, we cannot accurately account for 
the impact of individual treatments on the outcome of 
these patients. 
Thirteen studies addressed the role of high-dose che-
motherapy followed by stem cell transplantation in pa-
tients with metastatic and relapsed retinoblastoma.2-14 
Although metastatic retinoblastoma is more common 
in developing countries (secondary to late patient pre-
sentation/ diagnosis and lack of adequate healthcare 
facilities), only 3 reports originated from developing 
countries (including a case series jointly reported with a 
US institution).3,9,10 Possible explanations for the lack of 
relevant publications from developing counties include 
publication bias, reluctance to implement such novel, 
technically-demanding, non-evidence-based practices 
(stem cell transplantation) and the unbalanced physical 
distribution of care providers. Currently, the Children’s 
Oncology Group (COG) is undertaking a promising 
international study (COG ARET 0321) that aims at 
defining the most appropriate treatment strategy for 
patients with extraocular retinoblastoma.19 Results of 
this study are set to improve therapeutic outcomes for 
advanced retinoblastoma patients in developing coun-
tries. Overall, according to our review, treatment-related 
toxicity was as expected from a myeloablative high-dose 
chemotherapy regimen (grade IV myelosuppression 
and gastrointestinal toxicity) while treatment-associat-
ed mortality was rarely reported—only 1 of 77 patients 
(1.3%). The length of follow-up greatly varied between 
the included studies (from 2 to 103 months); however, 
this strategy achieved durable tumor control in approxi-
mately 60% of patients. Outcome appears to vary ac-
cording to location of metastatic spread; patients with 
non-CNS metastases fair better than those with CNS 
disease. This is possibly secondary to the poor CNS 
penetration of conventional chemotherapeutic agents; 
only 47.1% of patients who received thiotepa subse-
quently developed CNS relapse. Overall, the outcome 
of patients with metastatic and relapsed retinoblastoma 
treated by high-dose chemotherapy followed by stem 
cell transplantation appears to be superior to historical 
controls treated by conventional chemotherapy.8 
Three studies addressed the role of high-dose che-
motherapy followed by stem cell transplantation in 
patients with trilateral or bilateral advanced retinoblas-
toma.10,15,16 Due to the small number of included cases 
(17 patients), accurate assessment of the safety of this 
therapeutic regimen was not possible; however, the re-
ported morbidity/ mortality were within expectations 
(grade IV myelosuppression and 1 case of treatment-
Figure 1. Search strategy and study selection.
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  Study/date 
  published Study design Study period 
Country of 
origin 
Total number 
of patients
Number of 
patients 
with isolated 
relapse 
Number of 
patients 
with CNS: 
non-CNS 
metastases 
Response 
to induction 
CTX 
High-dose 
chemo-
therapy 
Adequate 
high-dose 
CTX regimen 
used? 
  namouni et 
  al2 1997
retros-
pective 1989-1994 France 19 7 4:8  
- 11 patients; 
complete 
response
- 7 patient; 
partial 
response
- 1 patient; 
Stable 
disease
CeC Yes
  palma et al3 
  2011
retros-
pective 2002-2008
3 centers 
in South 
america 
11 none 4:7
all patients 
had 
complete 
response
- 6 patients; 
CTe
- 4 patients; 
CeC
1 patient; 
meC
Yes
  Kremens et 
  al4 2003
retros-
pective 1992-2001 Germany 4 none 0:4
all patients 
had 
complete 
response
- 3 patients; 
CTe
1 patient; 
BCnU, 
etoposide
Yes
  Tsuruta et  
  al5 2011 Case report na Japan 1 none 1:0
Complete 
response Tm
no (platinum 
agent not 
used) 
  dunkel et 
  al6 2010b
retros-
pective 2000-2006 USa 8 1 7:0  
all patients 
achieved 
major/ 
complete 
response 
- 2 patients; 
CTe
- 2 patients; 
CeC
- 1 patient; 
CT
- 3 patients; 
none 
4/5c
  Hertzberg 
  et al7 2001 Case report na Germany 1 none 0:1
Complete 
response CTe Yes
Table 1. Characteristics and outcome for patients who underwent high-dose chemotherapy and peripheral blood stem cell transplant 
for metastatic or relapsed retinoblastoma.
aStudy included patients with involved cut end of optic nerve/extrasclear extension and patients presenting with disease relapse/distant metastases
bThese patients were treated after publication of the first report by the same authors 
cOnly 5 patients received high-dose chemotherapy
dOne of these patients also received iT radioimmunotherapy
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  Study/date 
  published Type of HSCT
Other 
treatments 
in addition to 
transplant  
Median 
follow-up 
period in 
months 
(range) 
Toxicity 
(number 
of patients 
affected/ 
total number 
of patients)
Treatment 
related 
mortality 
Survival at 
last follow-
up
Patterns 
of failure 
in patients 
with CNS 
metastases
CNS relapse 
following 
thiotepa 
Second 
malignancy 
  namouni et 
  al2 1997
auto in all 
patients
eBrT in 12 
patients 
(all CnS 
metastases 
patients 
received 
eBrT)
27 (5-74) not cleara none
- 12 patients 
were alive 
ned 
- 6 patients 
were ddTd
- 1 patient  
has pd
- 3/4 patients 
had relapse 
in the CnS 
and ddTd
na (none 
received 
thiotepa) 
not 
mentioned
  palma et al3 
   2011
auto in all 
patients
Cranial eBrT 
for 3 patients 
with CnS 
metastases 
39 (27-56)
no non-
hematolo-
gical grade 
iV toxicity 
none 7 patients alive ned 
- 2/4 patients 
had relapse 
in the CnS 
and ddTd
2/4 none
  Kremens et 
  al4 2003
auto in all 
patients 
iT mTX 
in the 
patient who 
developed 
lepto-
meningeal  
relapse  
33.5 (9-107)
Grade iii and 
iV Gi toxicity 
in 4/5
none
4 patients 
were alive 
ned (1 
patient 
developed 
lepto-
meningeal 
relapse 
but was 
salvaged)
na 0/3 not mentioned
  Tsuruta et  
  al5 2011 allo
High-dose 
Busulfan 
and 2nd 
HSCT 
followed by 
iT thiotepa 
and cytosine 
arabinoside 
followed by 
3rd pBSCT 
due to 
additional 
relapse
2 (na) not mentioned none
ddTd 2 
months after 
last HSCT
The patient 
had relapse 
in the CnS
1/1 none
  dunkel et 
  al6 2010 auto
- 2 patients; 
CSi
- 2 patients; 
focal eBrTd
12 (3-101) not mentioned
One patient 
died of 
toxicity 
while 
receiving 
induction 
CTX
- 5 patients 
ddTd
- 2 patients; 
alive ned
5/7 patients 
had CnS 
relapse  
2/3 not mentioned 
  Hertzberg et 
  al7 2001 auto none 48 (na)
late toxicity; 
hypergona-
do-tropic 
hypogona-
dism
none
alive ned na 0/1 none 
Table 1 cont. Characteristics and outcome for patients who underwent high-dose chemotherapy and peripheral blood stem cell 
transplant for metastatic or relapsed retinoblastoma.
aStudy included patients with involved cut end of optic nerve/extrasclear extension and patients presenting with disease relapse/distant metastases
bThese patients were treated after publication of the first report by the same authors 
cOnly 5 patients received high-dose chemotherapy
dOne of these patients also received iT radioimmunotherapy
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Table 1 cont. Characteristics and outcome for patients who underwent high-dose chemotherapy and peripheral blood stem cell 
transplant for metastatic or relapsed retinoblastoma.
  matsubara  
  et al8 2005
retros-
pective 1986-2000 Japan 5 none
2:3
all patients 
achieved 
complete 
response
- 2 patients; 
Cymp
- 2 patients; 
meC
- 1 patient; 
CyTm
Yes
  Chantada et 
  al9 2010 Case report 2002-2008 argentina 1
e none 1:0 Complete response CeC Yes
  dunkel et 
  al10 2010
retros-
pective 1997-2005
USa, 
argentina 6 none 6:0 
not 
mentioned
- 3 patients; 
none
- 1 patient; 
CT and 
topotecan
- 1 patient; 
Cym
- 1 patient; 
CTe, Cym
1/3f
  dimaras et 
 al11 2009 Case report na Canada 1 none 1:0
Complete 
response CeC Yes
  dunkel et 
  al12 2010
retros-
pective 1993-2006 USa 15 none 0:15
all patients 
achieved 
complete 
response
- 7 patients; 
CT and 
topotecan
- 5 patients; 
CTe
- 2 patients; 
none
- 1 patient; 
CT
5/13g
  Study/date 
  published Study design Study period 
Country of 
origin 
Total number 
of patients
Number of 
patients 
with isolated 
relapse 
Number of 
patients 
with CNS: 
non-CNS 
metastases 
Response 
to induction 
CTX 
High dose 
chemo-
therapy 
Adequate 
high-dose 
CTX regimen 
used? 
eThere was 1 patient who received high-dose chemotherapy followed-by HSCT in this prospective study
fOnly 3 patients received high-dose chemotherapy
gOnly 13 patients received high-dose chemotherapy
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  matsubara  
  et al8 2005
auto in all 
patients
- iT mTX in 
all patients
- 4/5 patients 
received 
eBrT to 
bulky sites 
- 2/2 patients 
with CnS 
metastases 
received 
cranial 
irradiation 
48 (4-113)
- all 
patients; 
grade iV 
mucositis 
- 1 patient; 
elevated 
liver 
enzymes 
none
- 3 patients; 
alive ned
- 2 patients; 
ddTd
2/2 patients 
had CnS 
relapse 
0/1 none
  Chantada et 
  al9 2010 auto none 5 (na)
not 
mentioned
not 
mentioned
This patient 
ddTd 5 
months after 
HSCT 
The patient 
had relapse 
in the CnS
This patient 
did not 
receive 
thiotepa
not 
mentioned 
  dunkel et 
  al10 2010
auto in all 
patients
- 2 patients; 
eBrT 
(site not 
specified)
- 1 patient; 
radio-
immuno-
therapy
17 (5-36) na none 
- 5 patients; 
ddTd
- 1 patient; 
alive ned
5/6 patients 
had CnS 
relapse 
1/2 na
  dimaras et 
  al11  2009 auto
periodic 
intraven-
tricular 
topotecan 
and 
cytarabine  
100 (na)
Grade iV 
myleo-
toxicity 
none alive ned 0/1
This patient 
did not 
receive 
thiotepa
none 
  dunkel et   
  al12 2010
auto in all 
patients
- 7 patients; 
eBrT to 
bulky sites  
103 (34-202) 
in alive ned 
patients
Grade iV 
myleo-
toxicity 
in most 
patients 
none
- 10 patients; 
alive ned
- 5 patients; 
ddTd
na (none 
had CnS 
metastases) 
2/2
- 3 patients; 
osteo-
sarcoma 
Table 1 cont. Characteristics and outcome for patients who underwent high-dose chemotherapy and peripheral blood stem cell 
transplant for metastatic or relapsed retinoblastoma.
  Study/date 
  published Study design Study period 
Country of 
origin 
Total number 
of patients
Number of 
patients 
with isolated 
relapse 
Number of 
patients 
with CNS: 
non-CNS 
metastases 
Response 
to induction 
CTX 
High dose 
chemo-
therapy 
Adequate 
high-dose 
CTX regimen 
used? 
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Table 1 cont. Characteristics and outcome for patients who underwent high-dose chemotherapy and peripheral blood stem cell 
transplant for metastatic or relapsed retinoblastoma.
Table 1 cont. Characteristics and outcome for patients who underwent high-dose chemotherapy and peripheral blood stem cell 
transplant for metastatic or relapsed retinoblastoma.
 rodriguez-
 Galindo et 
 al13 2003
retros-
pective na USa 4 none 0:4 
all patients 
achieved 
complete 
response
- 1 patient; 
Ce
- 1 patient; 
Cy and 
topotecan
- 1 patient; 
Cyme
1 patient; 
Cye and 
topotecan 
0/4
  Yamane et 
  al14 1999 Case report
HSCT done 
in 1994 Japan 1 none O:1
partial 
response
meC and iT 
mTX, ara-C, 
predniso-
lone 
Yes
  rodriguez- 
  Galindo et 
  al13 2003
auto in all 
patients 
all patients 
received 
eBrT to 
sites of bone 
metastases 
78 (44-88)
1 patient 
developed 
fungal 
sepsis 
none
- 2 patients; 
alive ned
- 2 patients; 
ddTd
na (none 
had CnS 
metastases) 
none of the 
patients 
received 
thiotepa 
na
Yamane et 
al14 1999 auto none 48 (na) na none alive ned
na (none 
had CnS 
metastases) 
na none
CT±e: Carboplatin, thiotepa, etoposide; eBrT: external-beam radiation therapy; CeC: Cyclophosphamide, etoposide, carboplatin; meC: melphalan, etoposide, carboplatin; Tm: 
Thiotepa, melphalan; pBSCT: peripheral blood stem cell transplantation; iT: intrathecal; ned: no evidence of disease; CnS: Central nervous system; ddTd: dead due to disease; 
pd: progressive disease; Gi: Gastrointestinal toxicity; CSi: Cranio-spinal irradiation; Cymp: Cyclophosphamide, melphalan, cisplatin; CyTm: Cyclophosphamide, thiotepa, 
melphalan; Cym: Cyclophosphamide, melphalan; CSF: Cerebrospinal fluid; CyT: Cyclophosphamide, thiotepa; mTX: methotrexate
  Study/date 
  published Study design Study period 
Country of 
origin 
Total number 
of patients
Number of 
patients 
with isolated 
relapse 
Number of 
patients 
with CNS: 
non-CNS 
metastases 
Response 
to induction 
CTX 
High dose 
chemo-
therapy 
Adequate 
high-dose 
CTX regimen 
used? 
  Study/date 
  published Study design Study period 
Country of 
origin 
Total number 
of patients
Number of 
patients 
with isolated 
relapse 
Number of 
patients 
with CNS: 
non-CNS 
metastases 
Response 
to induction 
CTX 
High dose 
chemo-
therapy 
Adequate 
high-dose 
CTX regimen 
used? 
systematic reviewreTinOBlaSTOma
Hematol Oncol Stem Cell Ther 5(2)     Second Quarter 2012 hemoncstem.edmgr.com 115
  Study Study design Study period Country of origin 
Number of 
patients Indication
Response to 
induction CTX
High dose 
chemotherapy 
Adequate 
high-dose 
CTX regimen 
used?
  dunkel 
  et al10 retrospective 1997-2005
USa, 
argentina 7
Trilateral 
disease 
not 
mentioned
- 2 patients; 
CTe
- 1 patient; CT
- 1 patient; 
none
- 1 patient; 
CyTe
- 1 patient; CT 
and topotecan
 - 1 patient; 
Cym
2/6a
  Giheeney et 
  al15 prospective  na USa 1
Trilateral 
disease 
not 
mentioned
CT and 
topotecan 0/1
  lee et al16 retrospective 2001-2006 South Korea 9
Bilateral 
advanced 
disease
-6 patients; pr
- 3 patients; 
Sd 
5 patients; 
CTe
4 patients; 
meC
9/9
aOnly 6 patients received high-dose chemotherapy
Table 2. Characteristics and outcome for patients who underwent high-dose chemotherapy and peripheral blood stem cell transplant 
for trilateral and bilateral advanced retinoblastoma
  Study Type of HSCT
Other 
treatments 
in addition to 
transplant  
Enucleation  
Median 
follow-up 
period in 
months 
(range) 
Toxicity 
(number 
of patients 
affected/ 
total number 
of patients)
Treatment 
related 
mortality 
Fuunctional eye 
preservation Survival
Second 
maligancy 
  dunkel 
  et al10
auto in all 
patients 
- 1 patient 
received 
eBrT
- 1 patient 
received iT 
topotecan
none 76 (3-104) na
1 patient 
died due to 
septicemia 
and multi-
organ 
system 
failure 
na
- 4 patients; 
alive ned
- 2 patients; 
ddTd
na
  Giheeney 
  et al15 auto
Gross tumor 
resection 
after 
transplant 
Yes, post 
transplant 59 (na) na none na alive ned none
  lee et al16 auto in all patients 
local 
therapy in at 
least one eye 
in 8 patients
Yes, post 
transplant in 
5 patients 
(5 eyes)
42 (22-82)
neutropenic 
fever: 9/9
Hepatic 
VOd: 2/9
none 
- 9/9 patients 
had at least one 
functional eye 
- 2/9 patients 
had both eyes 
preserved 
na none
CT±e: Carboplatin, thiotepa, etoposide; CyTe: Cyclophosphamide, thiotepa, etoposide; Cym: Cyclophosphamide, melphalan; eBrT: external-beam radiation therapy; meC: 
melphalan, etoposide, carboplatin; VOd: Veno-occlusive disease; pr: partial response; Sd: Stable disease 
Table 2 cont. Characteristics and outcome for patients who underwent high-dose chemotherapy and peripheral blood stem cell 
transplant for trilateral and bilateral advanced retinoblastoma
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  Study/date 
  published Study design Study period
Country of 
origin 
Number of 
patients Indication
Response 
to induction 
chemotherapy 
High dose 
chemotherapy 
Adequate 
high-dose 
CTX regimen 
used?
  namouni et 
  al2 1997 retrospective 1989-1994 France 6
a
- 5 patients; 
involved cut 
end of optic 
nerve
- 1 patient; 
extrascleral 
extension  
all patients 
achieved Cr CeC Yes
  Kremens et 
  al4 2003 retrospective 1992-2001 Germany 1
a
involved cut 
end of optic 
nerve and 
extrascleral 
extension 
Cr CTe Yes
CeC: Cyclophosphamide, etoposide, Carboplatin; CTe: Carboplatin, Thiotepa, etoposide; eBrT: external-beam radiation therapy; ned: no evidence of disease; Cr: Complete 
response; aBoth studies included patients with involved cut end of optic nerve/ extrasclear extension and patients presenting with disease relapse/ distant metastases.
Table 3. Characteristics and outcome for patients who underwent high-dose chemotherapy and peripheral blood stem cell transplant 
for tumor at the surgical margin of the optic nerve and/or extrascleral extension.
  Study/date 
  published Type of HSCT
Other 
treatments 
in addition 
to transplant
Enucleation  
Median 
follow-up 
period in 
months 
(range) 
Toxicity 
(number 
of patients 
affected/ 
total number 
of patients)
Treatment 
related 
mortality 
Fuunctional 
eye 
preservation 
Survival Second maligancy 
  namouni et 
  al2 1997
auto in all 
patients 
all patients 
received 
eBrT
no 29.5 (9-55) not cleara none not clear
all but one 
patient were 
alive ned at 
time of F/U
not 
mentioned 
  Kremens et 
  al4 2003 auto none na 8 (na)
Grade iii 
and iV Gi 
toxicity
none
involved eye 
enucleated 
before 
treatment 
alive ned not mentioned 
CeC: Cyclophosphamide, etoposide, Carboplatin; CTe: Carboplatin, Thiotepa, etoposide; eBrT: external-beam radiation therapy; ned: no evidence of disease; Cr: Complete 
response; aBoth studies included patients with involved cut end of optic nerve/ extrasclear extension and patients presenting with disease relapse/distant metastases.
Table 3 cont. Characteristics and outcome for patients who underwent high-dose chemotherapy and peripheral blood stem cell 
transplant for tumor at the surgical margin of the optic nerve and/or extrascleral extension.
related death). Nonethe ess, therapeutic outcome in 
these patients was superior to those presenting with 
metastatic disease (5 of the 7 evaluable patients [71.4%] 
were alive with no evidence of disease at the time of 
follow-up). 
Two studies addressed the role of high-dose che-
motherapy followed by stem cell transplantation in 
patients with tumor at the surgical margin of the optic 
nerve and/or extrascleral extension.2,4 In these patients, 
treatment-related toxicity was within expectations 
while excellent outcome was achieved (6 of 7 patients 
were alive with no evidence of disease at the time of 
follow-up). Traditionally, these patients were offered 
external-beam radiotherapy; however, this is associated 
with significant side effects. Several studies have re-
ported the occurrence of second malignancy following 
radiation therapy in retinoblastoma patients.20-22 This is 
especially true for patients with bilateral retinoblastoma 
since the majority harbor inherited germline mutations 
which predispose to cancer. We attempted to assess the 
systematic reviewreTinOBlaSTOma
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incidence of second malignancy in our review; however, 
and due to the short follow-up in most cases, most of 
the studies did not mention the occurrence of second 
malignancies in their respective patients. Furthermore, 
a significant proportion of the reviewed patients re-
ceived radiotherapy in addition to high-dose chemo-
therapy (38 patients), and as such, we were unable to 
derive rigid conclusions on the incidence of second 
malignancy in retinoblastoma patients treated by high-
dose chemotherapy followed by stem cell transplanta-
tion.2,3,6,8,10,12,13 In addition, radiation therapy has been 
linked with compromising the development and growth 
of orbital and facial bones during childhood.23 As a 
consequence, parents are often reluctant to accept this 
potential side effect of external-beam radiation therapy. 
In these situations, high-dose chemotherapy followed 
by stem cell transplantation poses as an alternative ap-
proach to adjuvant radiation therapy. 
In conclusion, this study represents the first detailed 
systematic review addressing the role of high-dose che-
motherapy followed by stem cell transplantation in reti-
noblastoma patients. High-dose chemotherapy (using 
a platinum agent, an alkylating compound and etopo-
side) followed by stem cell transplantation is an effec-
tive and well-tolerated treatment strategy in patients 
with retinoblastoma. Durable tumor control is possible 
in patients with non-CNS metastases, with trilateral or 
bilateral advanced retinoblastoma, and in patients with 
tumor at the surgical margin of the optic nerve and/or 
extrascleral extension. Patients with CNS metastases 
require thiotepa to improve tumor control.
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